Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rated "Hold" by Wall Street Analysts

Key Points

• Recursion Pharmaceuticals has a consensus “Hold” rating from five analysts, with one sell, two hold, and two buy recommendations. The average 12-month price target is $8.06.
• Shares recently fell 2.6% to $3.90. The company reported a quarterly loss of $0.25 per share and revenue of $7.67 million, both slightly below analyst expectations.
• Insiders have sold 157,408 shares worth $643,576 over the past 90 days, while institutional investors—which own 89.06% of the stock—have recently increased their positions.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) has received a consensus rating of "Hold" from the five brokerages that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $8.06.

A number of research analysts have weighed in on the stock. Wall Street Zen raised shares of Recursion Pharmaceuticals from a "strong sell" rating to a "sell" rating in a research note on Saturday, August 29th. Morgan Stanley set a $5.30 target price on Recursion Pharmaceuticals in a report on Monday, August 17th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th.

Recursion Pharmaceuticals Trading Down 2.6%

RXRX traded down $0.10 during trading on Tuesday, reaching $3.90. 3,680,416 shares of the company's stock were exchanged, compared to its average volume of 19,107,188. The stock has a market capitalization of $2.09 billion, a PE ratio of -3.79 and a beta of 1.04. The firm has a fifty day moving average price of $3.59 and a two-hundred day moving average price of $3.40. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a one year low of $2.77 and a one year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.01). The firm had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same period in the previous year, the company earned ($0.41) EPS. As a group, equities research analysts forecast that Recursion Pharmaceuticals will post -0.94 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, Director Robert Hershberg sold 25,000 shares of the firm's stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total value of $125,000.00. Following the completion of the sale, the director directly owned 162,156 shares of the company's stock, valued at $810,780. This trade represents a 13.36% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of the company's stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total transaction of $242,000.00. Following the completion of the sale, the director directly owned 6,108,287 shares of the company's stock, valued at $29,564,109.08. This represents a 0.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 157,408 shares of company stock worth $643,576. 6.65% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in RXRX. First Trust Advisors LP lifted its position in shares of Recursion Pharmaceuticals by 15.2% in the 1st quarter. First Trust Advisors LP now owns 2,610,726 shares of the company's stock worth $8,015,000 after buying an additional 344,035 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Recursion Pharmaceuticals by 18.2% in the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company's stock valued at $7,665,000 after buying an additional 384,486 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $7,370,000. Bank of New York Mellon Corp grew its position in shares of Recursion Pharmaceuticals by 29.3% during the 1st quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company's stock valued at $4,490,000 after buying an additional 331,048 shares during the last quarter. Finally, Swiss National Bank grew its position in shares of Recursion Pharmaceuticals by 21.8% during the 1st quarter. Swiss National Bank now owns 877,000 shares of the company's stock valued at $2,692,000 after buying an additional 156,700 shares during the last quarter. 89.06% of the stock is currently owned by institutional investors.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company's technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.